MECHANISM OF INCREASED PLASMA APO A1 LEVELS BY ESTROGENS

绝经后妇女比绝经前妇女有更高的冠心病（CHD）风险，即使在控制了年龄效应之后。 然而，雌激素替代疗法可显著降低绝经后妇女患冠心病的风险。 通过该研究，我们提出确定用以下方案中的每一种进行安慰剂对照、随机化治疗的绝经后妇女中载脂蛋白A-I（高密度脂蛋白的主要蛋白质组分）的动力学：安慰剂; B. 0.625mg/d结合雌激素; c.结合雌激素0.625mg/d+醋酸甲羟孕酮2.5mg/d。载脂蛋白A-1的动力学将通过稳定同位素技术来确定。低剂量雌激素（B）和雌激素-孕激素联合治疗（c）常用于绝经后妇女的激素替代治疗，但存在代谢和载脂蛋白动力学问题。

Postmenopausal women are at higher risk of coronary heart disease (CHD) than premenopausal women, even after controlling for age-effects. However, estrogen replacement therapy significantly lowers the risk of CHD in postmenopausal women. With the study, we propose to determine the kinetics of apolipoprotein A-1, the major protein component of high density lipoproteins, in postmenopausal women undergoing a placebo-controlled, randomized treatment with each of the following regimens: a. placebo; b. 0.625mg/d conjugated estrogens; c. 0.625mg/d conjugated estrogens + 2.5 mg/d medroxyprogesterone acetate. The kineetics of apo A-1 will be determined by stable isotope techniques. The low dose estrogen (b) and the estrogen-progestin combination (c) are frequently prescribed to postmenopausal women as hormone replacement therapy, but there are metabolism and apolipoprotein kinetics.